Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow, ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and ...

A recent publication in the International Journal of Cardiology, "Pulmonary artery denervation in pulmonary hypertension: A ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Individualized treatment and close monitoring are essential for pregnant women with pulmonary hypertension due to high maternal and fetal risks. Prognosis in pulmonary hypertension varies with ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

Report Ocean’s latest analysis delves into the “Vietnam Pulmonary Arterial Hypertension Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, ...